The pathogenicity of COVID-19 and the role of pentraxin-3: An updated review study

4Citations
Citations of this article
24Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

In recent years, the COVID-19 pandemic has become one of the most crucial scientific issues in the world, and efforts to eradicate the disease are still ongoing. The acute inflammatory reaction associated with this disease is associated with several complications such as cytokine storm, multiple organ damage, lung fibrosis, and blood clots. PTX3, as part of the humoral innate immune systems, is one of the acute-phase proteins that perform various functions, such as modulating inflammation, repairing tissue, and recruiting immune cells. PTX3 is increased in people with SARS-CoV-2, and its level decreases with proper treatment. Therefore, it can be regarded as a suitable marker for the prognosis of the COVID-19 and evaluating the effectiveness of the treatment method applied. However, some studies have shown that PTX3 can be a double-edged sword and develop tumors by providing an immunosuppressive environment.

Cite

CITATION STYLE

APA

Margiana, R., Sharma, S. K., Khan, B. I., Alameri, A. A., Opulencia, M. J. C., Hammid, A. T., … Jawhar, Z. H. (2022, October 1). The pathogenicity of COVID-19 and the role of pentraxin-3: An updated review study. Pathology Research and Practice. Elsevier GmbH. https://doi.org/10.1016/j.prp.2022.154128

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free